Who We Are

The Kidney Innovation Accelerator (KidneyX) is a public-private partnership between the US Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases. KidneyX seeks to improve the lives of the 850 million people worldwide currently affected by kidney diseases by accelerating the development of drugs, devices, biologics and other therapies across the spectrum of kidney care including prevention, diagnostics, and treatment.

Building off the success of similar public-private accelerators, KidneyX will engage a community of researchers, innovators, and investors to bring breakthrough therapies to patients through a series of prize competitions. ASN and HHS leaders are overseeing KidneyX's efforts to accelerate the pace of innovation in the development of disruptive approaches to kidney care and the development of new medical products, leading to solutions that will improve the lives of the millions of people worldwide affected by kidney diseases. We hope you will consider joining us in this effort.

Steering Committee

Amy P. Abernethy, MD, PhD

Food and Drug Administration (FDA)

Christopher P. Austin, MD

National Center for Advancing Translational Sciences,
National Institutes of Health

Robert M. Califf, MD, MACC

Verily/Alphabet

Elazer Edelman, MD, PhD

Massachusetts Institute of Technology

Jennifer Erickson

White House Office of Science and Technology Policy (2015-2017)

Paul E. Klotman, MD

Baylor College of Medicine

Emily Levy, MBA

Synergy Partners

Kevin Longino

National Kidney Foundation

Saira Ramasastry, MA, MS

Life Sciences Advisory

Anne Rohall

Senior Counselor, US Department of Health and Human Services

Prabir Roy-Chaudhury, MD, PhD, FASN, ASN Council Liaison

University of North Carolina

John R. Sedor, MD, FASN, Chair

Cleveland Clinic